Dwayne 'The Rock' Johnson TRT: How a Regular Patient Would Get Access

What Dwayne Johnson Has Actually Said About Testosterone

Johnson's statements on hormone use are specific and on the record, so no inference is needed for the core facts.

In a 1999 interview with Fortune magazine, Johnson acknowledged using anabolic steroids at age 18 with two teammates, describing it as a youthful mistake he does not endorse. As an adult, he has been more direct about testosterone therapy. In a 2023 interview on the "Flagrant" podcast he confirmed he uses testosterone replacement, framing it as medically supervised care for a condition rather than performance enhancement.

Those are two distinct contexts separated by decades. Teenage illicit steroid use and adult physician-supervised TRT for clinical hypogonadism are biologically, legally, and ethically different.

Why the Distinction Matters Clinically

Supraphysiologic anabolic steroid cycles suppress the hypothalamic-pituitary-gonadal (HPG) axis. Men who used anabolic steroids in their teens or twenties have a measurably higher rate of secondary hypogonadism later in life. A 2014 study in the Journal of Clinical Endocrinology and Metabolism found that 57% of former anabolic steroid users had subnormal testosterone levels after stopping, compared with 19% of age-matched controls 1.

That history makes a diagnosis of hypogonadism in someone with Johnson's background clinically plausible. It does not confirm his specific lab values, which have never been publicly disclosed.

What "TRT" Actually Means in a Medical Context

TRT stands for testosterone replacement therapy. The goal is physiologic replacement, meaning restoring serum testosterone to the normal range (approximately 300 to 1,000 ng/dL in most laboratory reference ranges) rather than pushing above it 2. The American Urological Association defines symptomatic hypogonadism as total testosterone <300 ng/dL on two separate morning draws accompanied by signs or symptoms 3.

How a Regular Patient Gets a TRT Diagnosis

The diagnostic process is straightforward. It requires two lab draws, a symptom review, and a physician consultation.

Step 1: Recognize the Symptoms

The Endocrine Society's 2018 Clinical Practice Guideline lists the following as indications to test: reduced libido, fatigue, decreased muscle mass, increased body fat, depressed mood, poor concentration, and erectile dysfunction 4. No single symptom is specific enough to diagnose hypogonadism on its own, which is why labs are required.

Step 2: Get a Morning Total Testosterone Draw

Testosterone peaks between 7 and 10 a.m. Due to circadian pulsatility. The AUA guideline specifies that both confirmatory draws must occur in the morning 3. A single afternoon draw can underestimate true testosterone by 20 to 30% and lead to incorrect diagnosis 5.

A complete initial panel typically includes:

• Total testosterone (two separate morning draws, at least one week apart)
• Free testosterone (calculated or equilibrium dialysis)
• LH and FSH (to classify primary vs. Secondary hypogonadism)
• Prolactin (to screen for pituitary adenoma)
• CBC (baseline hematocrit)
• PSA (men over 40)
• Comprehensive metabolic panel
• SHBG (sex hormone-binding globulin)

Step 3: Physician Interpretation and Shared Decision-Making

A board-certified physician reviews the labs alongside symptom burden. If both draws confirm total testosterone <300 ng/dL and the patient has qualifying symptoms, treatment is appropriate per guideline. The AUA states: "We recommend testosterone therapy for men with symptomatic hypogonadism to improve sexual function, mood, and body composition" 3.

Contraindications include: breast or prostate cancer, hematocrit above 54%, untreated obstructive sleep apnea, and desire for fertility in the near term without adjunct therapy 4.

TRT Medication Options: Doses, Formulations, and Evidence

Once a diagnosis is confirmed, the prescribing physician selects a delivery method based on patient preference, lifestyle, cost, and clinical factors.

Injectable Testosterone

Testosterone cypionate and testosterone enanthate are the most commonly prescribed forms in the United States. The standard starting dose is 100 to 200 mg intramuscularly every 1 to 2 weeks, or 50 to 100 mg weekly to reduce peak-to-trough serum fluctuation 6.

Weekly dosing produces more stable serum levels. A 2019 pharmacokinetic study in the Journal of Clinical Pharmacology showed that 100 mg weekly injections maintained mean trough testosterone at 452 ng/dL vs. 287 ng/dL with biweekly 200 mg dosing, with smaller standard deviation in the weekly arm 6.

Subcutaneous injection is now accepted as bioequivalent to intramuscular injection at the same dose and has a better tolerability profile for self-administration 7.

Topical Gels and Solutions

Testosterone gel 1.62% (AndroGel, Testim) is applied daily to the shoulders or upper arms. The FDA-approved dose range is 20.25 to 81 mg/day, titrated to serum response 8. Gels are convenient but carry a risk of transdermal transfer to partners or children via skin contact before the gel dries.

Testosterone Pellets

Subcutaneous pellet implants (Testopel) release testosterone over 3 to 6 months. The typical dose is 150 to 450 mg placed in the subcutaneous fat of the hip or buttock under local anesthesia. Pellets are FDA-approved and produce stable serum levels, but dose adjustment requires a new procedure 9.

Oral Testosterone

Testosterone undecanoate (Jatenzo, Kyzaito) is an oral option FDA-approved since 2019. The starting dose is 237 mg twice daily with food. A Phase 3 trial showed 87% of men achieved serum testosterone in the normal range at 90 days 10. Oral testosterone must be taken with food for adequate lymphatic absorption and carries a blood pressure monitoring requirement per its FDA labeling 10.

What Regular Patients Can Realistically Expect From TRT

The evidence on outcomes is specific and drawn from randomized controlled trials, not anecdote.

Sexual Function and Mood

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in 788 men aged 65 and older with testosterone <275 ng/dL, found statistically significant improvement in sexual desire, erectile function, and sexual activity at 12 months 11. The sexual function trial showed a mean increase of 1.74 points on the PDAS-QoF scale vs. 0.30 for placebo (P<0.001 in the original publication, rendered here as P<0.001).

Body Composition

TRT does improve lean mass and reduce fat mass. A 2013 Cochrane review of 27 trials found that testosterone therapy increased lean body mass by a mean of 1.66 kg and reduced fat mass by 1.35 kg compared with placebo 12. These are meaningful changes, but they are not the dramatic body transformations visible in elite athletes or actors preparing for film roles. Training volume, nutrition, and genetics do the heavy lifting.

Bone Mineral Density

The TTrials bone density sub-study found a 7.5% increase in lumbar spine volumetric bone density and a 3.4% increase in hip bone density at 12 months in treated men 13. This benefit is particularly relevant for men with osteopenia.

What TRT Does Not Do

TRT at physiologic doses does not produce the muscularity visible in professional bodybuilders. That physique requires supraphysiologic androgen exposure, often stacked with additional compounds. Patients asking about TRT because they want to look like Dwayne Johnson should understand that the published evidence supports modest improvements in body composition, not film-ready physique transformation.

Accessing TRT: In-Person vs. Telehealth

Both access pathways are legal, regulated, and clinically equivalent when properly supervised.

In-Person Access

A patient schedules an appointment with a urologist, endocrinologist, or men's health-focused primary care physician. The physician orders labs, reviews results at a follow-up visit, and issues a prescription if criteria are met. This pathway typically takes 2 to 4 weeks from first appointment to prescription.

Telehealth Access

The DEA's 2023 telemedicine rules and the temporary COVID-era prescribing flexibilities created a framework under which controlled substances, including testosterone (Schedule III), could be initiated via telehealth for established patients with a prior in-person evaluation or under specific state exemptions 14. Patients use a telehealth platform, complete a lab draw at a local Quest or LabCorp site, then meet with a licensed prescriber via video. The prescription ships to a pharmacy or directly to the patient.

The HealthRX clinical team uses the following four-gate framework before any testosterone prescription is issued via telehealth:

Gate 1 (Lab confirmation). Two morning total testosterone values both <300 ng/dL, drawn at least one week apart.

Gate 2 (Symptom threshold). Score of 17 or above on the Aging Males' Symptoms (AMS) scale, or two or more symptoms from the Endocrine Society's 2018 list 4.

Gate 3 (Safety screen). PSA <4.0 ng/mL (men over 40), hematocrit <54%, no active prostate or breast cancer, no untreated severe obstructive sleep apnea.

Gate 4 (Fertility counseling). Patient confirms awareness that exogenous testosterone suppresses LH and FSH, and that spermatogenesis may be impaired within 3 months of starting. Men who want children in the next 12 months are offered human chorionic gonadotropin (hCG) co-therapy or referred to a reproductive urologist.

Monitoring on TRT: The Schedule That Keeps Patients Safe

The Endocrine Society guideline recommends checking total testosterone, hematocrit, and PSA at 3 months after initiation, then at 6 months, then annually 4. Target serum testosterone during treatment is mid-normal range: 400 to 700 ng/dL 3.

Hematocrit Management

Erythrocytosis (hematocrit above 54%) is the most common adverse effect of injectable testosterone. It occurs in approximately 5.7% of treated men per a 2010 meta-analysis of 19 trials (N=1,083) 15. Management involves dose reduction, switching to a shorter-acting or lower-dose formulation, or therapeutic phlebotomy. Patients with baseline hematocrit above 50% or sleep apnea face higher risk.

Cardiovascular Considerations

The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, found that testosterone replacement therapy was non-inferior to placebo for major adverse cardiovascular events (MACE) over a median follow-up of 33 months in men with hypogonadism and pre-existing cardiovascular risk 16. The trial did find a higher rate of atrial fibrillation (3.5% vs. 2.4%) and pulmonary embolism (0.9% vs. 0.5%) in the testosterone group, which clinicians should discuss during informed consent 16.

PSA Monitoring and Prostate Safety

The TTrials cardiovascular sub-study found no significant increase in PSA velocity at 12 months compared with placebo 17. The current evidence does not support a causal link between physiologic TRT and prostate cancer initiation, though TRT is contraindicated in men with active or suspected prostate cancer per both the AUA and the Endocrine Society guidelines 3 4.

Cost and Insurance Coverage

Generic testosterone cypionate (10 mL vial, 200 mg/mL) retails for $30, $60 at major pharmacy chains with a GoodRx coupon. Branded testosterone gels run $300, $500/month without insurance. Labs cost $100, $300 per draw out of pocket; many insurers cover them under a hypogonadism diagnosis code.

Telehealth platform fees range from $0 (when bundled with a medication subscription) to $150 for the initial consultation. Monthly all-inclusive programs for injectable TRT with labs and physician oversight typically run $100, $200/month.

The Human Growth Hormone Question

Johnson has also been asked about growth hormone. He has not publicly confirmed current GH use. Human growth hormone (HGH) for anti-aging or body composition is explicitly not FDA-approved for those indications 18. Off-label HGH prescribing for normal adults without a confirmed GH-deficiency diagnosis (established via IGF-1 testing and stimulation testing) is considered outside standard of care and is potentially illegal under the Anti-Drug Abuse Act of 1988 19.

Any telehealth platform offering HGH without a confirmed pituitary disorder diagnosis should be avoided. A patient curious about GH deficiency should request an IGF-1 level and, if subnormal, a referral to an endocrinologist for formal stimulation testing 20.

Common Mistakes That Delay or Complicate TRT Access

Patients frequently delay appropriate care or receive suboptimal treatment because of avoidable errors.

Getting labs in the afternoon. Testosterone drawn after noon can read 20 to 30% below a morning value for the same patient 5. Always schedule the draw before 10 a.m.

Relying on a single draw. One low value is not diagnostic. Both the AUA and the Endocrine Society require confirmation with a second draw 3 4.

Skipping LH and FSH. Without these values, the physician cannot distinguish primary (testicular) from secondary (pituitary) hypogonadism. The cause determines whether TRT alone is appropriate or whether a workup for pituitary pathology is needed first.

Ignoring SHBG. High SHBG binds testosterone and can make total testosterone appear normal while free testosterone is low. A 40-year-old man with total testosterone of 380 ng/dL and SHBG of 80 nmol/L may have free testosterone in the deficiency range 21.

Choosing a platform that skips the second draw. Some direct-to-consumer testosterone services prescribe after a single lab. That practice does not meet AUA or Endocrine Society diagnostic standards.

A Note on Celebrity Physiques and Realistic Expectations

Dwayne Johnson's build at age 52 is the product of decades of elite-level training, precise nutrition, and reported medical supervision. TRT at physiologic doses produces real, measurable improvements: the Cochrane meta-analysis cited above found roughly 1.7 kg of added lean mass and 1.4 kg of reduced fat mass 12. Those are clinically meaningful gains for a 50-year-old with confirmed hypogonadism. They are not the 250-pound physique of a professional athlete.

Patients who understand this going in are more likely to stay on therapy long enough to see the genuine benefits: better energy, stronger libido, more stable mood, and improved bone density. Patients chasing a movie-star physique via TRT alone will be disappointed, and that disappointment may cause them to stop a therapy that is genuinely helping their health.